Synopsis
Synopsis
0
VMF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Alcon, Betaxolol
2. Alo 1401 02
3. Alo-1401-02
4. Alo140102
5. Betaxolol
6. Betaxolol Alcon
7. Betoptic
8. Betoptima
9. Hydrochloride, Betaxolol
10. Kerlon
11. Kerlone
12. Oxodal
13. Sl 75212
14. Sl-75212
15. Sl75212
1. 63659-19-8
2. Betaxolol Hcl
3. Betoptic
4. Kerlone
5. Betoptima
6. Lokren
7. Betaxolol (hydrochloride)
8. Alo 1401-02
9. Sl75212
10. Betaxolol Hydrochloride (betoptic)
11. Nsc-760048
12. Alo-1401-02
13. Betoptic S
14. Mls000863279
15. 6x97d2xt0o
16. Dextrobetaxolol (hydrochloride)
17. Kerlon
18. 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydrochloride
19. Alo-140102
20. Smr000058420
21. Sl-7521210
22. Sl 75.212-10
23. Sl-75.212-10
24. 1-(isopropylamino)-3-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)propan-2-ol Hydrochloride
25. Betaxolo Hydrochloride
26. 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanol Hydrochloride
27. 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, Hydrochloride, (+-)-
28. Chebi:643228
29. Chemical Name: 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanol Hydrochloride
30. Betaxolol Hydrochloride [usan]
31. Sr-01000000108
32. Einecs 264-384-3
33. Mfcd00242959
34. Sl-75212-10
35. Unii-6x97d2xt0o
36. Kerlong
37. Sl-75212
38. Levobetaxololhcl
39. Sl 75 212-10
40. Betoptic (tn)
41. Prestwick_779
42. Kerlone (tn)
43. Betaxolol Hydrochloride [usan:usp:jan]
44. Cpd000058420
45. Opera_id_878
46. (+-)-1-(p-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)-2-propanol Hydrochloride
47. 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-isopropylaminopropan-2-ol Hydrochloride
48. Chembl1691
49. Schembl42794
50. Mls000028464
51. Mls000758269
52. Mls001148209
53. Mls001424199
54. Mls002222261
55. Betaxolol Hydrochloride- Bio-x
56. Sl 75212 Hcl
57. Betaxolol For Peak Identification
58. Hy-b0381a
59. Dtxsid30979876
60. Mci-144
61. Hms1569m05
62. Pharmakon1600-01505512
63. (2s)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydrochloride
64. Bcp02967
65. Betaxolol Hydrochloride [mi]
66. Tox21_500193
67. Betaxolol Hydrochloride (jp17/usp)
68. Betaxolol Hydrochloride [jan]
69. Nsc760048
70. Akos015843993
71. Ac-1412
72. Bcp9000394
73. Betaxolol Hydrochloride [mart.]
74. Betaxolol Hydrochloride [vandf]
75. Ccg-101057
76. Ccg-213473
77. Lp00193
78. Nc00307
79. Nsc 760048
80. Betaxolol Hydrochloride [usp-rs]
81. Betaxolol Hydrochloride [who-dd]
82. Betaxolol Hydrochloride, >98% (hplc)
83. Ncgc00093669-01
84. Ncgc00093669-02
85. Ncgc00260878-01
86. As-18082
87. Bb164245
88. Bcp0726000249
89. B4474
90. Betaxolol Hydrochloride [orange Book]
91. Eu-0100193
92. Ft-0645228
93. S1827
94. Sw196917-4
95. Betaxolol Hydrochloride [ep Monograph]
96. B 5683
97. Betaxolol Hydrochloride [usp Monograph]
98. D00598
99. T71164
100. Kerledex Component Betaxolol Hydrochloride
101. 659x198
102. A803574
103. Betaxolol Hydrochloride Component Of Kerledex
104. Q-200714
105. Sr-01000000108-2
106. Sr-01000000108-4
107. Sr-01000000108-9
108. Betoptic Pilo Component Betaxolol Hydrochloride
109. Q27105180
110. Betaxolol Hydrochloride Component Of Betoptic Pilo
111. Betaxolol Hydrochloride, European Pharmacopoeia (ep) Reference Standard
112. Betaxolol Hydrochloride, United States Pharmacopeia (usp) Reference Standard
113. 1-(isopropylamino)-3-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)propan-2-ol Hcl
114. 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydron;chloride
115. 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanolhydrochloride
116. Betaxolol For Peak Identification, European Pharmacopoeia (ep) Reference Standard
117. (+/-)-1-(p-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)-2-propanol Hydrochloride
118. 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)propan-2-ol Hydrochloride;levobetaxolol Hydrochloride
119. 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, Hydrochloride, (+/-)-
120. 72424-72-7
| Molecular Weight | 343.9 g/mol |
|---|---|
| Molecular Formula | C18H30ClNO3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 11 |
| Exact Mass | 343.1914215 g/mol |
| Monoisotopic Mass | 343.1914215 g/mol |
| Topological Polar Surface Area | 50.7 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 286 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 6 | |
|---|---|
| Drug Name | Betaxolol hydrochloride |
| PubMed Health | Betaxolol (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Betaxolol Ophthalmic Solution USP, contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile isotonic solution. Betaxolol hydrochloride is a white, crystalline powder, soluble in water, with a molecular... |
| Active Ingredient | Betaxolol hydrochloride |
| Dosage Form | Solution/drops; Tablet |
| Route | Ophthalmic; Oral |
| Strength | 10mg; eq 0.5% base; 20mg |
| Market Status | Prescription |
| Company | Wockhardt; Epic Pharma; Kvk Tech; Bausch And Lomb; Akorn |
| 2 of 6 | |
|---|---|
| Drug Name | Betoptic |
| PubMed Health | Betaxolol (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | BETOPTIC Sterile Ophthalmic Solution contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile isotonic solution. Betaxolol hydrochloride is a white, crystalline powder, soluble in water, with a molec... |
| Active Ingredient | Betaxolol hydrochloride |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | eq 0.5% base |
| Market Status | Prescription |
| Company | Alcon |
| 3 of 6 | |
|---|---|
| Drug Name | Betoptic s |
| Active Ingredient | Betaxolol hydrochloride |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | eq 0.25% base |
| Market Status | Prescription |
| Company | Alcon |
| 4 of 6 | |
|---|---|
| Drug Name | Betaxolol hydrochloride |
| PubMed Health | Betaxolol (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | Betaxolol Ophthalmic Solution USP, contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile isotonic solution. Betaxolol hydrochloride is a white, crystalline powder, soluble in water, with a molecular... |
| Active Ingredient | Betaxolol hydrochloride |
| Dosage Form | Solution/drops; Tablet |
| Route | Ophthalmic; Oral |
| Strength | 10mg; eq 0.5% base; 20mg |
| Market Status | Prescription |
| Company | Wockhardt; Epic Pharma; Kvk Tech; Bausch And Lomb; Akorn |
| 5 of 6 | |
|---|---|
| Drug Name | Betoptic |
| PubMed Health | Betaxolol (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | BETOPTIC Sterile Ophthalmic Solution contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile isotonic solution. Betaxolol hydrochloride is a white, crystalline powder, soluble in water, with a molec... |
| Active Ingredient | Betaxolol hydrochloride |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | eq 0.5% base |
| Market Status | Prescription |
| Company | Alcon |
| 6 of 6 | |
|---|---|
| Drug Name | Betoptic s |
| Active Ingredient | Betaxolol hydrochloride |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | eq 0.25% base |
| Market Status | Prescription |
| Company | Alcon |
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Adrenergic beta-1 Receptor Antagonists
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Antagonists.)
Sympatholytics
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
71
PharmaCompass offers a list of Betaxolol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Betaxolol manufacturer or Betaxolol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Betaxolol manufacturer or Betaxolol supplier.
PharmaCompass also assists you with knowing the Betaxolol API Price utilized in the formulation of products. Betaxolol API Price is not always fixed or binding as the Betaxolol Price is obtained through a variety of data sources. The Betaxolol Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A ALO 1401 02 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ALO 1401 02, including repackagers and relabelers. The FDA regulates ALO 1401 02 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ALO 1401 02 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of ALO 1401 02 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A ALO 1401 02 supplier is an individual or a company that provides ALO 1401 02 active pharmaceutical ingredient (API) or ALO 1401 02 finished formulations upon request. The ALO 1401 02 suppliers may include ALO 1401 02 API manufacturers, exporters, distributors and traders.
click here to find a list of ALO 1401 02 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A ALO 1401 02 DMF (Drug Master File) is a document detailing the whole manufacturing process of ALO 1401 02 active pharmaceutical ingredient (API) in detail. Different forms of ALO 1401 02 DMFs exist exist since differing nations have different regulations, such as ALO 1401 02 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A ALO 1401 02 DMF submitted to regulatory agencies in the US is known as a USDMF. ALO 1401 02 USDMF includes data on ALO 1401 02's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ALO 1401 02 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of ALO 1401 02 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The ALO 1401 02 Drug Master File in Japan (ALO 1401 02 JDMF) empowers ALO 1401 02 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the ALO 1401 02 JDMF during the approval evaluation for pharmaceutical products. At the time of ALO 1401 02 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of ALO 1401 02 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a ALO 1401 02 Drug Master File in Korea (ALO 1401 02 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of ALO 1401 02. The MFDS reviews the ALO 1401 02 KDMF as part of the drug registration process and uses the information provided in the ALO 1401 02 KDMF to evaluate the safety and efficacy of the drug.
After submitting a ALO 1401 02 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their ALO 1401 02 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of ALO 1401 02 suppliers with KDMF on PharmaCompass.
A ALO 1401 02 CEP of the European Pharmacopoeia monograph is often referred to as a ALO 1401 02 Certificate of Suitability (COS). The purpose of a ALO 1401 02 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of ALO 1401 02 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of ALO 1401 02 to their clients by showing that a ALO 1401 02 CEP has been issued for it. The manufacturer submits a ALO 1401 02 CEP (COS) as part of the market authorization procedure, and it takes on the role of a ALO 1401 02 CEP holder for the record. Additionally, the data presented in the ALO 1401 02 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the ALO 1401 02 DMF.
A ALO 1401 02 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. ALO 1401 02 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of ALO 1401 02 suppliers with CEP (COS) on PharmaCompass.
A ALO 1401 02 written confirmation (ALO 1401 02 WC) is an official document issued by a regulatory agency to a ALO 1401 02 manufacturer, verifying that the manufacturing facility of a ALO 1401 02 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting ALO 1401 02 APIs or ALO 1401 02 finished pharmaceutical products to another nation, regulatory agencies frequently require a ALO 1401 02 WC (written confirmation) as part of the regulatory process.
click here to find a list of ALO 1401 02 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ALO 1401 02 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for ALO 1401 02 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture ALO 1401 02 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain ALO 1401 02 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ALO 1401 02 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of ALO 1401 02 suppliers with NDC on PharmaCompass.
ALO 1401 02 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ALO 1401 02 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ALO 1401 02 GMP manufacturer or ALO 1401 02 GMP API supplier for your needs.
A ALO 1401 02 CoA (Certificate of Analysis) is a formal document that attests to ALO 1401 02's compliance with ALO 1401 02 specifications and serves as a tool for batch-level quality control.
ALO 1401 02 CoA mostly includes findings from lab analyses of a specific batch. For each ALO 1401 02 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ALO 1401 02 may be tested according to a variety of international standards, such as European Pharmacopoeia (ALO 1401 02 EP), ALO 1401 02 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ALO 1401 02 USP).